Pacira BioSciences, Inc. PCRX R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.pacira.com

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Market & Price

Market Cap

$913.66M

Current Price

$23.22

High / Low (52W)

$27.22 / $19.16

Beta

0.32

Valuation

Stock P/E

178.62

Industry PE

23.65

Forward P/E

6.38

PEG Ratio

11.21

Book Value

$16.63

Price to Book

1.40

P/S

1.24

EV/EBITDA

9.26

Dividend Yield

Profitability & Returns

ROCE

2.75%

ROE

0.71%

ROA

1.35%

Profit Margin

0.70%

Op Margin

2.61%

EPS (Latest Qtr)

$0.07

EPS (TTM)

$0.13

Balance Sheet & Liquidity

Debt/Equity

0.63

Quick Ratio

3.01

Current Ratio

4.73

Debt

$411.18M

Total Assets

$1.26B

Current Assets

$547.97M

Working Capital

$427.38M

Ownership

Promoter Holding

1.74%

Chg in Prom Hold

FII / Inst Holding

115.58%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$1.12B

Total Revenue (TTM)

$734.86M

EBITDA

$121.29M

Free Cash Flow

$98.62M

Operating Cash Flow

$142.22M

Shares Outstanding

39.35M

Gross Margin

79.33%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

2.89%

Profit 5Y

-23.82%

Revenue (YoY)

5.00%

Earnings (YoY)

-30.00%

PROS

Generates positive free cash flow.

CONS

Trading at a high P/E of 178.6.
Earnings shrank at -23.8% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PCRX Pacira BioSciences, Inc. R2K	23.22	178.62	$913.66M	-	2.75%	0.71%	2.89%	-23.82%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	68.42M	70.14M	66.95M	-	74.29M	80.72M	82.71M	-	90.91M	101.82M	104.35M	-	105.68M	75.50M	117.48M	-	119.03M	135.59M	127.72M	157.99M	169.41M	167.47M	160.34M	169.47M	163.93M	167.12M	178.02M	-	-	168.92M	181.10M	179.52M	196.87M	177.38M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.31M	40.87M	34.28M	40.30M	36.41M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	134.62M	140.23M	145.24M	156.57M	140.96M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126.44M	131.10M	132.09M	167.50M	136.34M
Operating Income	5.11M	-	-2.25M	-6.44M	-20.86M	-	-14.05M	-15.78M	-3.57M	-	-6.94M	6.54M	4.05M	-	1.08M	5.28M	2.41M	-	17.09M	-7.15M	17.62M	-	19.44M	34.84M	31.43M	17.39M	31.23M	21.29M	-3.09M	39.88M	17.72M	13.21M	28.24M	-	-	8.18M	9.13M	13.15M	-10.92M	4.62M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33.61M	29.24M	34.37M	25.29M	29.51M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.73M	3.85M	3.65M	3.37M	3.18M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.71M	-1.93M	9.52M	571.00K	5.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.89M	2.92M	4.09M	-1.07M	2.08M
Net Income	3.09M	-2.50M	-3.85M	-7.96M	-22.16M	-3.97M	-19.87M	-19.74M	-7.60M	4.59M	-10.68M	2.56M	-640.00K	8.29M	-2.77M	2.73M	-6.09M	-4.89M	8.16M	-7.27M	130.12M	14.51M	10.37M	19.08M	17.66M	6.83M	19.88M	-693.00K	-19.54M	25.76M	10.86M	8.98M	18.89M	-	-	4.81M	-4.85M	5.43M	1.64M	2.92M
Diluted EPS	0.08	-	-	-	-0.59	-	-	-	-	-	-	0.06	-	-	-0.07	0.06	-0.15	-0.12	0.19	-0.17	2.94	0.32	0.23	0.42	0.39	0.15	0.40	-0.02	-0.43	0.51	0.23	0.19	0.39	-	-	0.10	-0.11	0.12	0.04	0.07
R&D Expense	5.89M	-	9.49M	9.36M	9.75M	-	16.63M	18.86M	11.78M	-	14.38M	12.24M	14.90M	-	14.38M	17.83M	20.25M	-	15.82M	13.62M	14.65M	-	15.88M	12.57M	11.58M	21.61M	26.28M	19.41M	17.14M	18.82M	20.83M	18.24M	20.34M	19.10M	-	25.34M	28.20M	25.97M	-	28.07M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	270.07M	284.34M	332.43M	418.93M	429.65M	541.53M	666.82M	674.98M	700.97M	726.41M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	199.29M	184.67M	170.43M	149.75M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	467.53M	490.31M	530.54M	576.66M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	407.50M	402.63M	440.67M	557.47M
Operating Income	-28.55M	-22.71M	-39.10M	-49.30M	-53.29M	-5.17M	9.46M	-32.02M	-24.94M	15.91M	10.48M	46.35M	89.92M	60.02M	87.67M	89.87M	19.19M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	140.38M	154.59M	29.12M	122.50M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	35.58M	17.31M	13.44M	14.61M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	13.30M	61.70M	-63.11M	16.87M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.61M	19.75M	36.45M	9.84M
Net Income	-31.71M	-27.15M	-43.33M	-52.28M	-63.91M	-13.72M	1.86M	-37.95M	-42.61M	-471.00K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M	7.03M
Diluted EPS	-	-	-	-	-1.93	-0.39	0.04	-1.02	-1.07	-0.01	-0.27	3.33	0.92	0.34	0.89	-2.15	0.16
R&D Expense	26.23M	18.63M	14.87M	9.94M	21.56M	18.73M	28.66M	45.68M	57.29M	55.69M	72.12M	59.42M	55.55M	84.80M	76.26M	81.58M	117.31M

Compounded Sales Growth

5 Years:	2.89%
1 Year:	5.00%

Compounded Profit Growth

5 Years:	-23.82%
1 Year:	-30.00%

Stock Price Performance

1 Year:	-10.14%
6 Months:	+0.22%
3 Months:	+5.98%
1 Month:	-7.64%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	66.56M	113.49M	112.05M	169.82M	326.07M	387.74M	391.47M	628.37M	689.35M	831.07M	1.27B	-	1.68B	1.57B	1.55B	1.26B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	498.33M	509.99M	745.13M	547.97M
Cash & Equivalents	12.39M	7.08M	26.13M	46.17M	12.52M	12.52M	37.52M	56.98M	35.94M	54.13M	132.53M	78.23M	99.96M	-	104.14M	153.30M	276.77M	158.54M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.06M	104.35M	125.28M	152.86M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98.40M	105.56M	113.30M	124.07M
Total Liabilities	-	-	114.94M	65.22M	46.20M	128.57M	154.93M	169.34M	172.49M	348.89M	368.13M	476.12M	654.83M	-	906.19M	704.26M	775.17M	571.81M
Current Liabilities	-	-	16.32M	31.91M	14.16M	121.94M	140.01M	149.79M	44.84M	56.22M	60.66M	107.67M	253.33M	-	147.77M	97.38M	309.92M	120.59M
Long Term Debt	-	-	21.87M	18.54M	25.19M	0	-	-	-	-	-	-	-	-	655.82M	513.80M	383.55M	372.19M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	763.39M	586.04M	638.85M	418.20M
Total Equity	7.49M	-22.95M	-48.38M	48.27M	65.86M	41.25M	171.15M	218.39M	218.98M	279.48M	321.23M	354.94M	619.69M	-	775.01M	870.13M	778.35M	693.11M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.93M	46.48M	47.08M	47.89M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-	-	-	17.79M	48.87M	70.52M	77.03M	-	145.27M	154.65M	189.39M	151.99M
Investing Cash Flow	-	-	-	-	-	-	-	-	-223.76M	20.58M	-128.49M	-277.61M	-	-225.19M	77.54M	-83.28M	99.48M
Financing Cash Flow	-	-	-	-	-	-	-	-	224.16M	8.95M	3.67M	222.30M	-	-401.53M	-183.03M	17.36M	-369.63M
Capital Expenditure	-5.51M	-6.77M	-6.17M	-18.26M	-12.17M	-22.98M	-40.30M	-24.71M	-19.27M	-14.51M	-10.16M	-37.80M	-	-30.08M	-15.16M	-10.64M	-15.33M
Free Cash Flow	-	-	-	-	-	-	-	-	-1.48M	34.36M	60.36M	39.23M	-	115.20M	139.49M	178.75M	136.66M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-481.44M	49.16M	123.48M	-118.15M
Share Buybacks	-	2.00K	-	-	-	-	-	-	-	-	-	-	-	0	0	25.00M	148.33M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	70.1%	72.6%	75.7%	79.4%
Operating Margin %	-	-	-	-	-	-	-	-11.9%	-8.8%	4.8%	2.5%	10.8%	16.6%	9.0%	13.0%	12.8%	2.6%
Net Margin %	-	-	-	-	-	-	-	-14.1%	-15.0%	-0.1%	-2.6%	33.9%	7.8%	2.4%	6.2%	-14.2%	1.0%
ROE %	138.2%	56.1%	-89.8%	-79.4%	-154.9%	-8.0%	0.8%	-17.3%	-15.2%	-0.1%	-3.1%	23.5%	-	2.1%	4.8%	-12.8%	1.0%
ROCE %	-	-45.2%	-47.9%	-50.4%	-111.3%	-2.8%	4.0%	-9.2%	-4.4%	2.5%	1.4%	4.5%	-	3.9%	5.9%	7.2%	1.7%

Shareholding Pattern

Insiders

1.74%

Institutions

115.58%

Public Float

117.63%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	17.12%	6.74M	$156.39M
2	Doma Perpetual Capital Management LLC	7.06%	2.78M	$64.50M
3	Vanguard Portfolio Management LLC	6.36%	2.50M	$58.08M
4	Dimensional Fund Advisors LP	5.24%	2.06M	$47.85M
5	Shaw D.E. & Co., Inc.	5.04%	1.98M	$46.04M
6	State Street Corporation	4.88%	1.92M	$44.57M
7	Renaissance Technologies, LLC	4.64%	1.83M	$42.39M
8	Vanguard Capital Management LLC	4.53%	1.78M	$41.43M
9	Goldman Sachs Group Inc	3.99%	1.57M	$36.45M
10	Morgan Stanley	3.54%	1.39M	$32.33M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PCRX

No recent headlines available.

PCRX · Healthcare